Given its ability to stimulate T cell proliferation, IL-2 has been used as a cancer immunotherapy since the 1980s, when it was described in the use of metastatic melanoma and renal cell carcinoma [13,14,15]. Here, IL2 is linked to hereditary clear cell renal cell carcinoma.